Cargando…

The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?

Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-3...

Descripción completa

Detalles Bibliográficos
Autores principales: Świerczyńska, Karolina, Krajewski, Piotr K., Nowicka-Suszko, Danuta, Białynicki-Birula, Rafał, Krajewska, Magdalena, Szepietowski, Jacek C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955714/
https://www.ncbi.nlm.nih.gov/pubmed/35324695
http://dx.doi.org/10.3390/toxins14030197
_version_ 1784676403908706304
author Świerczyńska, Karolina
Krajewski, Piotr K.
Nowicka-Suszko, Danuta
Białynicki-Birula, Rafał
Krajewska, Magdalena
Szepietowski, Jacek C.
author_facet Świerczyńska, Karolina
Krajewski, Piotr K.
Nowicka-Suszko, Danuta
Białynicki-Birula, Rafał
Krajewska, Magdalena
Szepietowski, Jacek C.
author_sort Świerczyńska, Karolina
collection PubMed
description Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group (p < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, p = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP.
format Online
Article
Text
id pubmed-8955714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89557142022-03-26 The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? Świerczyńska, Karolina Krajewski, Piotr K. Nowicka-Suszko, Danuta Białynicki-Birula, Rafał Krajewska, Magdalena Szepietowski, Jacek C. Toxins (Basel) Article Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group (p < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, p = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP. MDPI 2022-03-07 /pmc/articles/PMC8955714/ /pubmed/35324695 http://dx.doi.org/10.3390/toxins14030197 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Świerczyńska, Karolina
Krajewski, Piotr K.
Nowicka-Suszko, Danuta
Białynicki-Birula, Rafał
Krajewska, Magdalena
Szepietowski, Jacek C.
The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title_full The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title_fullStr The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title_full_unstemmed The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title_short The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
title_sort serum level of il-31 in patients with chronic kidney disease-associated pruritus: what can we expect?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955714/
https://www.ncbi.nlm.nih.gov/pubmed/35324695
http://dx.doi.org/10.3390/toxins14030197
work_keys_str_mv AT swierczynskakarolina theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT krajewskipiotrk theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT nowickasuszkodanuta theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT białynickibirularafał theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT krajewskamagdalena theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT szepietowskijacekc theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT swierczynskakarolina serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT krajewskipiotrk serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT nowickasuszkodanuta serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT białynickibirularafał serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT krajewskamagdalena serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect
AT szepietowskijacekc serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect